Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated.

Muna Al HashmiKonduru S SastryLee SilcockLotfi ChouchaneValentina MatteiNicola JamesRebecca MathewDavide BedognettiValeria De GiorgiDaniela MurtasWei LiuAouatef ChouchaneRamzi TemanniBarbara SeligerEna WangFrancesco M MarincolaSara Tomei

Published in: Journal of translational medicine (2020)

Cell lines carrying V600E mutation at the DNA level may respond differently to BRAF targeted treatment potentially due to a lower V600E RNA expression.

Keyphrases

wild type
metastatic colorectal cancer
poor prognosis
cancer therapy
nucleic acid
cell free
single molecule
combination therapy